
    
      This study will be a multicenter (approximately 30 sites), randomized, vehicle-controlled,
      double-blind, and parallel group design. Approximately 264 subjects with moderate to severe
      plaque psoriasis will be randomized to treatment with DFD-06 Cream or Vehicle Cream. Subjects
      will use study product twice daily for 14 days. Subject visits are scheduled at Screening,
      Baseline (Day 1) and Days 4, 8, and 15. Clinical determinations of disease severity will be
      performed using the total sign score (TSS) for the target lesion and Investigator Global
      Assessment (IGA) for overall severity.
    
  